Agios Pharmaceuticals (NASDAQ:AGIO) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

I fell for its charm three summers ago, wandering past whitewashed villas with sky-blue rooves to the shore of Agios Nikitas, a tiny fishing village where the water has an otherworldly quality.

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases ...

Agios Pharmaceuticals' focus is on expanding Pyrukund's label to treat thalassemia and sickle cell disease, targeting multi-billion dollar markets. Despite promising Phase 3 results, safety ...

CAMBRIDGE, MA – Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a biopharmaceutical company focused on cellular metabolism to treat cancer and rare genetic diseases, announced the upcoming departure ...

Agios Pharma submitted a sNDA to the FDA after two Phase III trials studying PYRUKYND (mitapivat) in thalassemia met their primary endpoints last year. The FDA has set a goal date of Sept. 7th ...

8 analysts have shared their evaluations of Agios Pharmaceuticals (NASDAQ:AGIO) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below ...

Drone view of Agios Nikitas, Lefkada, Greece. Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring ...

On our anniversary we blow the budget at an expensive, sophisticated hotspot, Amente, high in the hills beyond Agios Nikitas. There, we enjoy elegant cocktails and fine dine on scallops and black ...